From the Research
The Admilparent trial demonstrated that 60-mg admilparant slowed lung function decline and was safe and well tolerated in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), supporting its potential use in these conditions. The trial, which was a phase 2, randomized, double-blind, placebo-controlled study, included parallel cohorts of patients with IPF and PPF who received 30 mg of admilparant, 60 mg of admilparant, or placebo twice daily for 26 weeks 1. The results showed that the rate of change in percentage of predicted FVC over 26 weeks for IPF was -2.7% (placebo), -2.8% (30 mg), and -1.2% (60 mg), and for PPF was -4.3% (placebo), -2.9% (30 mg), and -1.1% (60 mg). The treatment differences between 60-mg admilparant and placebo were 1.4% (95% confidence interval, -0.1 to 3.0) for IPF and 3.2% (95% confidence interval, 0.7 to 5.7) for PPF. The treatment effect was observed with or without background antifibrotics in both cohorts. Some key points to consider when using admilparant include:
- The medication was well tolerated, with diarrhea occurring at similar frequencies in admilparant arms versus placebo
- Transient Day 1 postdose blood pressure reductions were observed in all arms in both cohorts, but were greater with admilparant
- Treatment discontinuations because of adverse events were similar across IPF arms and lower with admilparant (2.5% [30 mg]; 0% [60 mg]) versus placebo (17.1%) for PPF The Admilparent trial provides evidence for the potential use of admilparant in patients with IPF and PPF, and further evaluation in phase 3 trials is warranted 1.